Bioject Medical Technologies (Bioject Medical Technologies) COGS-to-Revenue : 0.59 (As of Sep. 2011)

View and export this data going back to . Start your Free Trial

What is Bioject Medical Technologies COGS-to-Revenue?

Bioject Medical Technologies's Cost of Goods Sold for the three months ended in Sep. 2011 was $1.85 Mil. Its Revenue for the three months ended in Sep. 2011 was $3.14 Mil.

Bioject Medical Technologies's COGS to Revenue for the three months ended in Sep. 2011 was 0.59.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Bioject Medical Technologies's Gross Margin % for the three months ended in Sep. 2011 was 41.06%.

Bioject Medical Technologies COGS-to-Revenue Historical Data

The historical data trend for Bioject Medical Technologies's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioject Medical Technologies COGS-to-Revenue Chart

Bioject Medical Technologies Annual Data

Trend

Mar01

Mar02

Dec03

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

COGS-to-Revenue

Get a 7-Day Free Trial

0.73

0.70

0.65

0.61

0.69

Bioject Medical Technologies Quarterly Data
	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11
COGS-to-Revenue	Get a 7-Day Free Trial															0.69	0.70	0.60	0.53	0.59

Bioject Medical Technologies COGS-to-Revenue Calculation

Bioject Medical Technologies's COGS to Revenue for the fiscal year that ended in Dec. 2010 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	3.864	/	5.577
	=	0.69

Bioject Medical Technologies's COGS to Revenue for the quarter that ended in Sep. 2011 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1.853	/	3.144
	=	0.59

Bioject Medical Technologies (OTCPK:BJCT) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Bioject Medical Technologies's Gross Margin % for the three months ended in Sep. 2011 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	1.853 / 3.144
	=	41.06 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Bioject Medical Technologies COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Bioject Medical Technologies's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioject Medical Technologies (Bioject Medical Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bioject Medical Technologies Inc (OTCPK:BJCT) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.bioject.com

Bioject Medical Technologies Inc commenced operations in 1985 and is a developer and manufacturer of needle-free injection therapy systems (NFITS). The Companys long-term goal is to become supplier of needle-free injection systems to the pharmaceutical and biotechnology industries. It focused its business development efforts on new and existing licensing and supply agreements with pharmaceutical and biotechnology companies, as well as numerous research agreements that could guide to long-term agreements. The Companys pipeline of prospective new partnerships remains active. It is also actively pursuing additional opportunities both domestically and overseas as it expands its current product line. The Companys Biojector 2000 system (B2000) consists of two components: a hand-held, reusable jet injector and a sterile, single-use, disposable plastic syringe capable of delivering variable doses of medication up to 1.0 mL. Drug Reconstitution System - The needle-free drug reconstitution system allows for the transfer of diluents to reconstitute powdered medications into liquid form and withdrawal of liquid medication into a syringe without the use of a needle. Vitajet - The Vitajet is also composed of two components, a portable injector unit and a disposable syringe. It is smaller and lower in cost than other products in its needle-free offering. ZetaJet - The ZetaJet is Biojects latest advance in needle-free delivery systems. It consists of two components, the portable injector and an auto-disabling disposable syringe. The medical equipment market is very competitive. Bioject Medical Technologies has two patents: Biojector 2000 and Vitajet. The Companys products and manufacturing operations are subject to extensive government regulations, both in the U.S. and abroad. In the U.S., the Food and Drug Administration (FDA) administers the Federal Food, Drug and Cosmetic Act (FFDCA) and has adopted regulations to administer the FFDCA.

Executives

James C Gale	director	152 W 57TH STREET, 19TH FLOOR, NEW YORK NY 10019
Sanders Morris Harris Inc/fa	10 percent owner, other: See General Remarks	600 TRAVIS, SUITE 5900, HOUSTON TX 77002
David S Tierney	director	C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Edward L Flynn	director, 10 percent owner	211 SOMERVILLE ROAD RTE 202N, BEDMINISTER NJ 07921
Life Sciences Opportunities Fund Ii Lp	10 percent owner	152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019
Lof Partners Llc	other: See general remarks	152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019
Life Sciences Opportunities Fund Instittutional Ii Lp	10 percent owner	152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019
Randal D Chase	director	28 GEORGIA COURT, RICHMOND HILL A6 L4E ON7
Brigid Makes	director	20245 SW 95TH AVENUE, TUALATIN OR 97062
J Michael Redmond	officer: Sr. VP Bus Dev.	10 CANTERBURY ROAD, WINDHAM NH 03087
Elan Corp Plc	10 percent owner	TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN 2 L2 00000
Elan International Services Ltd	10 percent owner	C/O TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN L2 2
Elan Pharmaceutical Investments Ltd	10 percent owner	102 ST JAMES COURT, FIETSS SMITH FL BERM D0 9999999999
John P Gandolfo	officer: CFO	62 TERRACE ROAD, WAYNE NJ 07470
Grace K Fey	director	1210 CROMWELL ROAD, HALIFAX NOVA SCOTIA A5 B3H4L2

Bioject Medical Technologies (Bioject Medical Technologies) Headlines

No Headlines